Retraction: Procollagen Lysyl Hydroxylase 2 Is Essential for Hypoxia-Induced Breast Cancer Metastasis (Mol Cancer Res (2013) 11 (456–466) DOI: 10.1158/1541-7786.MCR-12-0629);Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis

Molecular Cancer Research

Volumn 11, Issue 5, 2013, Pages 456-466

  Gilkes, Daniele M ^a,b,e   Bajpai, Saumendra ^e,f   Wong, Carmen C ^a,b   Chaturvedi, Pallavi ^a,b   Hubbi, Maimon E ^a,b   Wirtz, Denis ^e,f   Semenza, Gregg L ^a,b,c,d,e  

^a Institute for Cell Engineering   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Department of Pediatrics ^*  (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; PROCOLLAGEN LYSINE 2 OXOGLUTARATE 5 DIOXYGENASE; PROCOLLAGEN LYSYL HYDROXYLASE 1; PROCOLLAGEN LYSYL HYDROXYLASE 2; PROCOLLAGEN LYSYL HYDROXYLASE 3; UNCLASSIFIED DRUG;

ARTICLE; BREAST BIOPSY; BREAST CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84877899680     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-23-0654     Document Type: Erratum

References (64)

1. Dewhirst MW. Intermittent hypoxia furthers the rationale for hypoxiainducible factor-1 targeting. Cancer Res 2007;67:854-5.
2. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med 2007;85:1301-7.
3. Gillies RJ, Gatenby RA. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 2007;26:311-7.
4. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-34.
5. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
6. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007;67:4157-63.
7. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW, et al. Evaluating hypoxia-inducible factor-1α as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005;65:7249-58.
8. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor- 1a is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007;67:563-72.
9. Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012;31:1757-70.
10. Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A 2011;108: 16369-74.
11. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1a independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97:1573-81.
12. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al. Overexpression of hypoxia-inducible factor 1a is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831-7.
13. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, et al. Hypoxia-inducible factor-1a expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006;12:4562-8.
14. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, et al. Hypoxia-inducible factor 1a is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 2008;110:465-75.
15. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, et al. Overexpression of hypoxia-inducible factor HIF-1a predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005;116:734-9.
16. Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, et al. Hypoxia-inducible factor-2a correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 2008;68:9212-20.
17. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
18. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008; 10:201.
19. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med 2008;6:11.
20. Hasebe T, Tsuda H, Tsubono Y, Imoto S, Mukai K. Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation. Jpn J Cancer Res 1997;88:590-9.
21. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006;4:38.
22. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 2007;67:2649-56.
23. Wang W, Wyckoff JB, Frohlich VC, Oleynikov Y, Huttelmaier S, Zavadil J, et al. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res 2002;62:6278-88.
24. Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, et al. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 2011;178:1221-32.
25. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005;8:241-54.
26. Lopez JI, Mouw JK, Weaver VM. Biomechanical regulation of cell orientation and fate. Oncogene 2008;27:6981-93.
27. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009;139:891-906.
28. Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet 2004;20:33-43.
29. Kivirikko KI. Collagen biosynthesis: a mini-review cluster. Matrix Biol 1998;16:355-6.
30. Knott L, Bailey AJ. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 1998; 22:181-7.
31. Prockop DJ, Kivirikko KI. Heritable diseases of collagen. N Engl J Med 1984;311:376-86.
32. van der Slot AJ, van Dura EA, de Wit EC, De Groot J, Huizinga TW, Bank RA, et al. Elevated formation of pyridinoline cross-links by profibrotic cytokines is associated with enhanced lysyl hydroxylase 2b levels. Biochim Biophys Acta 2005;1741:95-102.
33. Valtavaara M, Szpirer C, Szpirer J, Myllyla R. Primary structure, tissue distribution, and chromosomal localization of a novel isoform of lysyl hydroxylase (lysyl hydroxylase 3). J Biol Chem 1998;273:12881-6.
34. Steinmann B, Raghunath M. Delayed helix formation of mutant collagen. Science 1995;267:258.
35. Yeowell HN, Walker LC, Murad S, Pinnell SR. A common duplication in the lysyl hydroxylase gene of patients with Ehlers Danlos syndrome type VI results in preferential stimulation of lysyl hydroxylase activity and mRNA by hydralazine. Arch Biochem Biophys 1997;347:126-31.
36. van der Slot AJ, Zuurmond AM, Bardoel AF, Wijmenga C, Pruijs HE, Sillence DO, et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 2003;278: 40967-72.
37. Takaluoma K, Lantto J, Myllyharju J. Lysyl hydroxylase 2 is a specific telopeptide hydroxylase, while all three isoenzymes hydroxylate collagenous sequences. Matrix Biol 2007;26:396-403.
38. Robins SP. Biochemistry and functional significance of collagen crosslinking. Biochem Soc Trans 2007;35:849-52.
39. Brinckmann J, Acil Y, Tronnier M, Notbohm H, Batge B, Schmeller W, et al. Altered x-ray diffraction pattern is accompanied by a change in the mode of cross-link formation in lipodermatosclerosis. J Invest Dermatol 1996;107:589-92.
40. van der Slot AJ, Zuurmond AM, van den Bogaerdt AJ, Ulrich MM, Middelkoop E, Boers W, et al. Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon. Matrix Biol 2004;23:251-7.
41. Wu J, Reinhardt DP, Batmunkh C, Lindenmaier W, Far RK, Notbohm H, et al. Functional diversity of lysyl hydroxylase 2 in collagen synthesis of human dermal fibroblasts. Exp Cell Res 2006;312:3485-94.
42. Takaluoma K, Hyry M, Lantto J, Sormunen R, Bank RA, Kivirikko KI, et al. Tissue-specific changes in the hydroxylysine content and crosslinks of collagens and alterations in fibril morphology in lysyl hydroxylase 1 knock-out mice. J Biol Chem 2007;282:6588-96.
43. Steinmann B, Eyre DR, Shao P. Urinary pyridinoline cross-links in Ehlers-Danlos syndrome type VI. Am J Hum Genet 1995;57:1505-8.
44. Schito L, Rey S, Tafani M, Zhang H, Wong CC, Russo A, et al. Hypoxiainducible factor 1-dependent expression of platelet-derived growth factor Bpromotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci U S A 2012;109:E2707-16.
45. Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, et al. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) 2012;90: 803-15.
46. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440:1222-6.
47. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009;15:35-44.
48. Cailleau R, Olive M, Cruciger QV. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 1978;14:911-5.
49. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 2009;69:5292-3.
50. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1a and insulin-like growth factor 2. Cancer Res 1999;59:3915-8.
51. Berg RA. Determination of 3- and 4-hydroxyproline. Methods Enzymol 1982;82(Pt A):372-98.
52. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006;9:121-32.
53. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated datamining platform. Neoplasia 2004;6:1-6.
54. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
55. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005;7:R953-64.
56. Hofbauer KH, Gess B, Lohaus C, Meyer HE, Katschinski D, Kurtz A. Oxygen tension regulates the expression of a group of procollagen hydroxylases. Eur J Biochem 2003;270:4515-22.
57. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, et al. Digoxin and other cardiac glycosides inhibit HIF-1a synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008;105:19579-86.
58. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996;29:225-9.
59. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009;326:1216-9.
60. Dong S, Nutt CL, Betensky RA, Stemmer-Rachamimov AO, Denko NC, Ligon KL, et al. Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol 2005;64:948-55.
61. Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, Bose MV, Gopal G, et al. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer 2011;11:80.
62. Arao T, Yanagihara K, Takigahira M, Takeda M, Koizumi F, Shiratori Y, et al. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer 2006;118:483-9.
63. Noda T, Yamamoto H, Takemasa I, Yamada D, Uemura M, Wada H, et al. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver Int 2012; 32:110-8.
64. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.